Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639942 | 1.00 | POLB (0.98) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL16730155 | 0.81 | ABCB1 (0.71) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL15540233 | 0.81 | ABCB1 (0.71) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL15540629 | 0.81 | ABCB1 (0.71) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL16730153 | 0.81 | ABCB1 (0.71) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL14027346 | 0.79 | POLB (0.63) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL8891090 | 0.79 | HTR1A (0.70) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL1330304 | 0.78 | POLB (0.62) | POLBABCB1KMT2AMEN1ADRB2 | |
| SCHEMBL22639858 | 0.78 | LMNA (0.72) | POLBABCB1KMT2AMEN1LMNA | |
| SCHEMBL22640047 | 0.78 | LMNA (0.72) | POLBABCB1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | POLB 2262/4885ABCB1 265/4885KMT2A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.